Skip to content
Markets

GSK Shares Fall Nearly 5% as Shingrix and Arexvy Miss Forecasts Despite a Profit Beat

GSK shares fell 4.7% to 1,834p after Shingrix and Arexvy vaccine sales missed forecasts by 8% and 16%, overshadowing third-quarter core operating profit of £3.08bn that beat the £2.93bn consensus.

Automated production assembly line at GSK's Ware manufacturing site, UK (2953 x 1970 jpeg)
Photo: GSK

GSK shares fell 4.7% to 1,834p in London on Wednesday morning after sales of its Shingrix shingles vaccine and Arexvy RSV vaccine missed forecasts. That overshadowed a third quarter in which core operating profit rose 5% at constant exchange rates to £3.08bn, well ahead of expectations.

Most of the numbers beat what analysts had pencilled in. Turnover of £8.89bn was 0.6% above a company-compiled consensus of £8.84bn, and core earnings per share of 54.6p compared with 50.4p expected, according to AJ Bell. But the market focused on vaccines, the one large division that went backwards.

MeasureQ3 2026Consensus
Turnover£8.89bn£8.84bn
Core operating profit£3.08bn£2.93bn
Core EPS54.6p50.4p
Specialty Medicines£3.88bn£3.85bn
Vaccines£2.58bn£2.62bn
General Medicines£2.43bn£2.37bn

Vaccines were the weak spot

Vaccine sales fell 2% at constant exchange rates to £2.6bn. Shingrix, GSK's biggest vaccine, fell 5% to £0.8bn and came in about 8% below forecasts. Arexvy fell 24% to £0.2bn, roughly 16% short of expectations. GSK's results statement did not give a reason for either decline.

Meningitis vaccines were the bright spot, growing 12% to £0.6bn. GSK also won Japanese approval for a pre-filled syringe version of Shingrix.

Label

  • -4.7% GSK shares, Wednesday morning
  • -5% Shingrix sales, to £0.8bn
  • -24% Arexvy sales, to £0.2bn
GSK quality-control lab operator at work at the Ware site (1092 x 728 jpeg, below 1200 px).
GSK quality-control lab operator at work at the Ware site (1092 x 728 jpeg, below 1200 px). Photo: GSK

Specialty medicines carried the quarter

Specialty Medicines grew 15% to £3.9bn. HIV medicines, sold through ViiV Healthcare, rose 10% to £2.1bn. Respiratory, immunology and inflammation grew 21% to £1.1bn, and oncology grew 23% to £0.6bn. General Medicines was stable at £2.4bn, with the Trelegy inhaler up 8% to £0.8bn.

Profit benefited from a better product and regional mix and from royalty income of £258m, against £224m expected, while selling and administrative costs were lower than forecast. JPMorgan analysts noted that the earnings beat was proportionally much larger than the sales beat, reflecting a higher gross margin, more royalty income and lower overheads.

Reported figures were weaker. Total operating profit fell 16% at constant rates to £2.13bn and total EPS fell 21% to 38.5p, mainly because of £328m of restructuring charges for GSK's Accelerate Growth programme. Cash generated from operations rose 24% to £3.12bn, and free cash flow was £2.1bn.

Guidance held, not raised

Chief executive Luke Miels said: "GSK has delivered another strong quarter." The company kept its 2026 forecasts at constant exchange rates rather than raising them:

GSK's 2026 guidance

  • Turnover growth of 3% to 5%, now expected towards the upper half
  • Core operating profit growth of 7% to 9%, towards the upper half
  • Core EPS growth of 7% to 9%, towards the lower half
  • A full-year dividend of 70p expected, with 17p declared for the third quarter

GSK also said it remains on track for more than £40bn of sales in 2031, and that it expects its operating margin to be stable or improving while its HIV drug dolutegravir loses patent protection between 2028 and 2030.

What investors watch next

With the vaccine business shrinking, the investment case leans more heavily on the pipeline. GSK listed US and Japanese approvals for Hibsago in chronic hepatitis B, a US approval for Jemperli in a form of rectal cancer and positive registrational data for Jideytro in first-line lung cancer. It has started a phase III trial of an mRNA seasonal flu vaccine, and 18 of the 22 phase III starts planned for 2026 are already under way.

Before the results, GSK shares closed at £18.94 on 23 October, up 1.69% that week and about 2% above their level at the end of August. Wednesday's fall takes them back below that August level, and the next test is whether Shingrix and Arexvy sales stabilise in the fourth quarter.

Sources

Related stories

Markets

AstraZeneca Jumps 7%, Its Best Day in a Year, as Third-Quarter Profit Beats Forecasts

AstraZeneca shares rose nearly 7%, their best day in about a year, after third-quarter core EPS of $2.79 beat the $2.59 forecast and cancer drug sales grew 17%. It kept its 2026…

Markets

Unilever Raises Its Volume Target, but Shares Slip as Developed Markets Shrink

Unilever shares fell 2.2% to 4,785p even as third-quarter underlying sales grew 5.2%, beating the 4.8% forecast, and volume guidance rose to at least 3%, because sales in developed…

Markets

HSBC Shares Slide as Revenue Misses Forecasts and Wealth Growth Stalls

HSBC shares fell nearly 7% at the open as Q3 revenue of $18.6bn missed the $19bn forecast and wealth revenue stalled, overshadowing a 32% rise in pre-tax profit to $9.6bn.

Markets

Novartis Raises Its Profit Outlook Despite a $1.9bn Writedown on Del-desiran

Novartis raised its 2026 profit guidance as Q3 core operating income rose 10% to $6.04bn, beating the $5.51bn expected, even as a $1.9bn del-desiran writedown cut reported profit…

Markets

Bitcoin Falls to $62,000 as $2bn of Leveraged Bets Are Wiped Out in Sixth Weekly Loss

Bitcoin fell to about $62,000 at the weekend as $2bn of leveraged bets were liquidated, its sixth straight weekly loss. It was back near $65,000 on Monday, with $60,000 the next…

Markets

Copper Hits a Four-Month Low at $13,210 as AI Doubts Drag European Miners Down 2.3%

Copper fell to $13,210 a tonne on Monday, a four-month low about 10% below September's record, as AI doubts and weak Chinese data hit metals and Europe's basic resources shares…

Markets

Bessent Urges an Outside CEO for Nvidia as Shares Fall 4.1% Before Results

Treasury Secretary Scott Bessent wants Nvidia to hire an outside chief executive, the board is not discussing Jensen Huang's return, and the shares fell 4.1% on Monday, a day…

Markets

Chip Index Sinks 5.28% With All 30 Stocks Down, Dragging the Nasdaq 2.49% Before Nvidia

The Philadelphia Semiconductor Index fell 5.28% on Monday 16 November with all 30 members down, pulling the Nasdaq 2.49% lower and the Dow down 739 points before Nvidia reports.